Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

This study is currently recruiting participants.
Verified February 2014 by Stanford University
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Stanford University
ClinicalTrials.gov Identifier:
NCT00568490
First received: December 4, 2007
Last updated: February 12, 2014
Last verified: February 2014

December 4, 2007
February 12, 2014
September 1998
April 2016   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00568490 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers
Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

To correlate tumor oxygenation as measured by the Eppendorf electrode with the serum level of secreted proteins known to be induced by tumor hypoxia.

The endpoints of the study are

  1. To validate the prognostic significance of OPN in H&N and lung cancer patients and to monitor its level during active therapy and follow up for cancer surveillance.
  2. To identify a gene and protein signature for hypoxia in H&N and lung cancer patients.
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Description:

blood, tumor tissue

Non-Probability Sample

Newly diagnosed patients with head and neck cancer

  • Head and Neck Cancer
  • Lung Cancer
  • Lip Cancer
  • Lip Neoplasms
  • Head and Neck Cancers
  • Procedure: Tumor biopsy
    For patients who undergo tumor biopsy or resection at Stanford, approximately 500 mg of the tumor will be removed from the resection specimen
  • Procedure: Phlebotomy
    Blood draw (approximately 20 cc) prior to any anticancer therapy Weekly blood draw (approximately 20cc) only for patients who are undergoing radiation treatment at Stanford University
    Other Name: Blood draw
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
600
April 2017
April 2016   (final data collection date for primary outcome measure)

Inclusion Criteria:Newly diagnosed patients with head and neck cancer who has tumor accessible to tumor oxygenation measurement with a microelectrode.

Both
18 Years and older
No
Contact: Cato Chan 650-724-4606 catochan@stanford.edu
United States
 
NCT00568490
ENT0016, 15310; CA67166, 73995, SU-11052007-801
Not Provided
Stanford University
Stanford University
National Institutes of Health (NIH)
Principal Investigator: Quynh-Thu Le Stanford University
Stanford University
February 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP